Skip to main content
SpringerLink
Log in

Pharmacokinetics and Pharmacodynamics of Meropenem in Elderly Chinese with Lower Respiratory Tract Infections

Population Pharmacokinetics Analysis Using Nonlinear Mixed-Effects Modelling and Clinical Pharmacodynamics Study

  • Original Research Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Background: Meropenem is a broad-spectrum antibacterial that is usually used in the treatment of serious lower respiratory tract infections (LRTIs). However, there is a lack of published studies exploring the correlation between the population pharmacokinetics of meropenem, the clinical pharmacodynamics of the drug and the response to the drug in Chinese patients with LRTIs, especially in the elderly.

Objective: The aim of this study was to develop a pharmacokinetic model of meropenem using patient data and use this to explore the clinical pharmacodynamics of meropenem in the treatment of LRTIs in elderly Chinese patients.

Methods: We measured serum meropenem concentrations in patients who had received meropenem 0.5 or 1.0 g infused over 0.5 hours every 8 or 12 hours, respectively. The pharmacokinetic analysis of meropenem was performed using nonlinear mixed-effects modelling (NONMEM®) software. The minimum inhibitory concentration (MIC) of meropenem against Gram-negative bacilli was tested by the E-test method. The pharmacodynamic parameters of percentage of time above MIC (%T>MIC), the ratio of the drug area under the serum concentration-time curve to MIC (AUC/MIC), the ratio of the maximum serum concentration of the drug to MIC (Cmax/MIC) and the ratio of the minimum serum concentration of the drug to MIC (Cmin/MIC) were analysed for their association with clinical and bacteriological outcomes.

Results: A total of 284 serum meropenem concentration measurements were obtained from 75 patients (aged 63–95 years). A two-compartment model fitted the concentration data best. The covariates creatinine clearance (CLCR) and Acute Physiology and Chronic Health Evaluation (APACHE) II score had the most significant effects on meropenem pharmacokinetics. Forty-five patients were enrolled in the pharmacodynamic study, including 25 clinical responders and 21 patients with bacteriological eradication. All of the 45 patients had Gram-negative bacilli isolated from tracheal aspirate or sputum. The %T>MIC, AUC/MIC, Cmax/MIC and Cmin/MIC values for the 25 clinical responders were significantly higher than those for the nonresponders (all p < 0.05). However, logistic regression analysis showed that only %T>MIC independently influenced clinical outcome (p = 0.001, odds ratio [OR] = 1.065). The cut-off value for predicting clinical success using %T>MIC was 76%; the sensitivity and specificity of %T>MIC for predicting a successful response were 84% and 85%, respectively. The %T>MIC, AUC/MIC, Cmax/MIC and Cmin/MIC values, and the serum level of albumin, for the 21 patients with bacteriological eradication were significantly higher than those for patients with bacteriological treatment failure (all p <0.05). Logistic regression analysis showed that %T>MIC (p = 0.008, OR = 1.047) and serum level of albumin (p = 0.033, OR = 1.434) independently influenced bacteriological eradication.

Conclusions: To our knowledge, this is the first study to investigate the population pharmacokinetics and clinical pharmacodynamics of meropenem in elderly Chinese. CLCR and APACHE II score have significant influences on meropenem pharmacokinetics. In LRTI patients, the cut-off value of 76% for %T>MIC can be applied to optimize their meropenem dose regimen to achieve clinical success.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1
Fig. 2
Fig. 3
Table III
Fig. 4

Similar content being viewed by others

References

  1. Capelastegui A, España PP, Bilbao A, et al. Study of community-acquired pneumonia: incidence, patterns of care, and outcomes in primary and hospital care. J Infect 2010 Nov; 61(5): 364–71

    Article  PubMed  Google Scholar 

  2. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005 Feb; 171(4): 388–416

    Article  Google Scholar 

  3. Song JH. Asian Hospital Acquired Pneumonia Working Group. Treatment recommendations of hospital-acquired pneumonia in Asian countries: first consensus report by the Asian HAP Working Group. Am J Infect Control 2008 May; 36(4 Suppl.): S83–92

    Article  PubMed  Google Scholar 

  4. Torres A, Ewig S, Lode H, et al. Defining, treating and preventing hospital acquired pneumonia: European perspective. Intensive Care Med 2009 Jan; 35(1): 9–29

    Article  PubMed  Google Scholar 

  5. Li C, Kuti JL, Nightingale CH, et al. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol 2006 Oct; 46(10): 1171–8

    Article  PubMed  CAS  Google Scholar 

  6. Lee DG, Choi SM, Shin WS, et al. Population pharmacokinetics of meropenem in febrile neutropenic patients in Korea. Int J Antimicrob Agents 2006 Oct; 28(4): 333–9

    Article  PubMed  CAS  Google Scholar 

  7. Ikawa K, Morikawa N, Ikeda K, et al. Population pharmacokinetics and pharmacodynamics of meropenem in Japanese pediatric patients. J Infect Chemother 2010 Apr; 16(2): 139–43

    Article  PubMed  CAS  Google Scholar 

  8. van den Anker JN, Pokorna P, Kinzig-Schippers M, et al. Meropenem pharmacokinetics in the newborn. Antimicrob Agents Chemother 2009 Sep; 53(9): 3871–9

    Article  PubMed  Google Scholar 

  9. Bradley JS, Sauberan JB, Ambrose PG, et al. Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate. Pediatr Infect Dis J 2008 Sep; 27(9): 794–9

    Article  PubMed  Google Scholar 

  10. Du X, Li C, Kuti JL, et al. Population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients. J Clin Pharmacol 2006 Jan; 46(1): 69–75

    Article  PubMed  CAS  Google Scholar 

  11. Doh K, Woo H, Hur J, et al. Population pharmacokinetics of meropenem in burn patients. J Antimicrob Chemother 2010 Nov; 65(11): 2428–35

    Article  PubMed  CAS  Google Scholar 

  12. Isla A, Rodríguez-Gascón A, Trocóniz IF, et al. Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy. Clin Pharmacokinet 2008; 47(3): 173–80

    Article  PubMed  CAS  Google Scholar 

  13. Roberts JA, Kirkpatrick CM, Roberts MS, et al. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009 Jul; 64(1): 142–50

    Article  PubMed  CAS  Google Scholar 

  14. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005 Dec; 26(6): 1138–80

    Article  PubMed  CAS  Google Scholar 

  15. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008 Jun; 36(5): 309–32

    Article  PubMed  Google Scholar 

  16. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16(1): 31–41

    Article  PubMed  CAS  Google Scholar 

  17. Drusano GL, Hutchison M. The pharmacokinetics of meropenem. Scand J Infect Dis Suppl 1995; 96: 11–6

    PubMed  CAS  Google Scholar 

  18. Elmadfa I, Meyer AL. Body composition, changing physiological functions and nutrient requirements of the elderly. Ann Nutr Metab 2008; 52Suppl. 1: 2–5

    Article  PubMed  CAS  Google Scholar 

  19. Craig WA. The pharmacology of meropenem, a new carbapenem antibiotic. Clin Infect Dis 1997 Feb; 24Suppl. 2: S266–75

    Article  PubMed  CAS  Google Scholar 

  20. Ariano RE, Nyhlén A, Donnelly JP, et al. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother 2005 Jan; 39(1): 32–8

    Article  PubMed  CAS  Google Scholar 

  21. Li C, Du X, Kuti JL, et al. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 2007 May; 51(5): 1725–30

    Article  PubMed  CAS  Google Scholar 

  22. Koromath FS, Sumarmi, Hermawan AG. Infectious disease pattern and serum albumin levels in elderly people hospitalized at Dr. Moewardi Hospital Surakarta during 2004. Acta Med Indones 2008 Jul; 40(3): 114–6

    PubMed  Google Scholar 

  23. Agulló-Ortuño MT, García-Mancebo ML, Montes-Ares O, et al. Biochemical and immunologic features of an outbreak of Legionnaires disease: comparative study between community-acquired pneumonias. Diagn Microbiol Infect Dis 2006 Sep; 56(1): 7–11

    Article  PubMed  Google Scholar 

  24. Hung PP, Lin YH, Lin CF, et al. Chryseobacterium meningosepticum infection: antibiotic susceptibility and risk factors for mortality. J Microbiol Immunol Infect 2008 Apr; 41(2): 137–44

    PubMed  Google Scholar 

  25. Wells M, Lipman J. Measurements of glomerular filtration in the intensive care unit are only a rough guide to renal function. S Afr J Surg 1997 Feb; 35(1): 20–3

    PubMed  CAS  Google Scholar 

  26. Pong S, Seto W, Abdolell M, et al. 12-hour versus 24-hour creatinine clearance in critically ill pediatric patients. Pediatr Res 2005 Jul; 58(1): 83–8

    Article  PubMed  Google Scholar 

  27. Herrera-Gutiérrez ME, Seller-Pérez G, Banderas-Bravo E, et al. Replacement of 24-h creatinine clearance by 2-h creatinine clearance in intensive care unit patients: a singlecenter study. Intensive Care Med 2007 Nov; 33(11): 1900–6

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors have no conflicts of interest that are directly relevant to the content of this study. No sources of funding were used to conduct this study or prepare this manuscript.

Author information

Authors and Affiliations

  1. Department of Respiratory Medicine, Peking University Third Hospital, No. 49 North Garden Rd, Haidian District, Beijing, 100191, China

    Qing-tao Zhou &  Bei He

  2. Department of Pharmacy, Peking University Third Hospital, Beijing, China

    Chao Zhang & Suo-di Zhai

  3. Department of Clinical Laboratory, Peking University Third Hospital, Beijing, China

    Zhen-ying Liu & Jie Zhang

Authors
  1. Qing-tao Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bei He
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chao Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Suo-di Zhai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhen-ying Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jie Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bei He.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhou, Qt., He, B., Zhang, C. et al. Pharmacokinetics and Pharmacodynamics of Meropenem in Elderly Chinese with Lower Respiratory Tract Infections. Drugs Aging 28, 903–912 (2011). https://doi.org/10.2165/11595960-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11595960-000000000-00000

Keywords

Search

Navigation